Nasopharyngeal Carcinoma

Moreover, miR-10b-3p levels were inversely correlated with ITGAV expression in NPC tissues. Collectively, these findings identify an EBV-regulated miR-10b-3p/ITGAV/STAT5-ERK1/2 axis in NPC and show that loss of miR-10b-3p promotes tumor growth and metastasis by relieving ITGAV repression, suggesting potential therapeutic targets for EBV-associated NPC.

Our findings contribute to a more nuanced understanding of LEL-ICC pathogenesis and highlight the potential synergistic role of viral co-infections. Further case accumulation and mechanistic studies are needed.

Our results identify TRIM47 as a novel E3 ligase responsible for SDHB ubiquitination and degradation, thereby promoting Warburg-like metabolism and NPC progression. These findings unveil the TRIM47-SDHB axis as a promising therapeutic target and support metabolic intervention with ascorbate as a potential precision strategy for NPC treatment.

Our findings suggest that glycerophospholipid metabolism may play an important role in NPC progression and highlight the potential of AGPAT3, DGAT2, SLC44A1, AGPAT5, and LPGAT1 as diagnostic and prognostic markers. This study provides novel insights into the metabolic interactions within the NPC microenvironment, providing insights for potential targeted therapeutic interventions.

P1, N=9, Recruiting, West China Hospital

PSMC2 upregulates CPT1 and GPX4 by activating STAT3, inhibits ferroptosis induced by lipid peroxidation, and drives malignant proliferation and metastasis in NPC.

P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026

Through the dual pathways of " IL-12-EMT/VM inhibition" and "CXCL13-TLS construction," TIL-B cooperatively restrains tumor invasion and metastasis, building a multidimensional immune defense system. This study demonstrates that TIL-B play an important regulatory role in anti-tumor immunity in NPC and suggests their therapeutic potential, providing a rationale for the development of B cell-based or TLS-targeted immunotherapeutic strategies.

P=N/A, N=900, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P2, N=30, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Mar 2028 --> Oct 2026 | Recruiting --> Active, not recruiting

AS IV inhibited PD-L1 expression in NPC via targeting the SATB2/Wnt/β-catenin axis, thereby activating CD8+ T cells, amplifying immunological responses, and ultimately inhibiting NPC growth. Graphical Abstract.

Collectively, the clinical experience underscores the safety, durability, and therapeutic potential of EBVSTs across EBV-associated diseases. Continued innovation in engineering and antigen targeting is poised to broaden VST applicability and support development of widely available cell therapies for EBV-associated and other cancers.